Efectos del estrés sobre los procesos de plasticidad y neurogénesis: una revisión / Effects of Stress on Plasticity and Neurogenesis: A Review

Grandes esfuerzos han sido llevados a cabo para entender los componentes psicobiológicos del estrés y de algunas de las psicopatologías relacionadas con él, tales como los trastornos de ansiedad (ansiedad generalizada o crisis de pánico) e incluso la depresión. Existen evidencias de que procesos como la neurogénesis y la plasticidad se ven enormemente afectados por muchos factores, entre ellos el estrés. En esta revisión se presentan algunos de los principales conceptos sobre la relación entre estrés, plasticidad y neurogénesis, a los que se ha llegado a partir de investigaciones realizadas -principalmente en modelos animales-, desde hace algunas décadas. Se realizará una diferenciación entre los efectos ocasionados por estrés crónico y agudo, tratando de establecer las interacciones que sobre estos efectos ejercen algunas variables tales como el género o el rango de edad, se enfatizarán los efectos comportamentales para finalmente revisar algunas de las formas de intervención actualmente más usadas para el tratamiento del estrés.

There is a growing interest in the comprehension of psychobiological mechanisms underlying stress and its relationships with many psychopathologies such as anxiety (i.e. generalized anxiety and panic attacks) or depression. There are several reports on the effects of stress on neurogenesis and plasticity. This review will discuss some of the core concepts on the relation between stress, plasticity and neurogenesis obtained during the last decades from research - mainly based in the use of animal models. The distinguishable effects between acute and chronic stress will also be discussed in relation to other factors as genre and age with an emphasis on behavioral effects. Some current therapeutic approaches will be reviewed as well.

Levofloxacin versus clarithromycin in a 10 day triple therapy regimen for first-line Helicobacter pylori eradication: a single-blind randomized clinical trial.

BACKGROUND: There is growing evidence that the standard triple therapy against Helicobacter pylori infection is losing clinical effectiveness. A triple therapy regimen with levofloxacin, amoxicillin and a proton pump inhibitor has been reported to be effective and well tolerated, and this regimen has been suggested as an alternative first-line treatment. The aim of this single-blind randomized clinical trial was to compare the eradication success of two first-line triple therapy regimens in the north of Spain: clarithromycin, amoxicillin and omeprazole (CAO) versus levofloxacin, amoxicillin and omeprazole (LAO). MATERIALS AND METHODS: A total of 250 consecutive patients diagnosed by conventional methods with H. pylori infection were randomized into one of two 10 day therapeutic regimens: standard CAO (n = 128) or LAO (n = 122). Eradication was confirmed by the (13)C-urea breath test. Adverse effects and compliance were also assessed. The clinical trial registration number was HPL08001HCLAD (EudraCT: 2008-001892-31). RESULTS: Intention-to-treat cure rates were: CAO, 75.0% (96/128; 95% CI: 66.6%-82.2%) and LAO, 82.8% (101/122; 95% CI: 74.9%-89.0%). Per-protocol cure rates were: CAO, 78.0% (96/123; 95% CI: 69.7%-85.0%) and LAO, 83.1% (98/118; 95% CI: 75.0%-89.3%). There were no statistically significant differences in effectiveness between the two regimens. In addition, no relevant differences in compliance or adverse effects were demonstrated. CONCLUSIONS: Levofloxacin-based treatment for H. pylori infection did not improve upon the eradication rate of the standard clarithromycin-based triple therapy in this study. This may reflect the progressive increase in in vitro resistance rates to levofloxacin observed in our region.

Hepatoportal sclerosis: a cause of portal hypertension to bear in mind / Hepatoportal sclerosis: a cause of portal hypertension to bear in mind

No disponible